The results demonstrated that the number of CD4+ and CD8+ T lymphocyte cells in the peripheral blood of tumor-bearing mice treated with Ad-hLF significantly increased compared with that of the control group (P<0.05) and was near to that of normal mice (P>0.05) (Fig. 4). The gene discussed is CD4; the disease is neoplasm.